These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 29244540)

  • 21. Future delivery of the Drug Interventions Programme: do the benefits justify the costs?
    Osborne A
    J Forensic Leg Med; 2013 Oct; 20(7):816-20. PubMed ID: 24112327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medicaid insurance policy for youths involved in the criminal justice system.
    Evans Cuellar A; Kelleher KJ; Rolls JA; Pajer K
    Am J Public Health; 2005 Oct; 95(10):1707-11. PubMed ID: 16131641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circumvention tourism.
    Cohen G
    Cornell Law Rev; 2012 Sep; 97(6):1309-98. PubMed ID: 23072007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breaking the addictive cycle of the system: improving US criminal justice practices to address substance use disorders.
    Kopak AM
    Int J Prison Health; 2015; 11(1):4-16. PubMed ID: 25751703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The disparate treatment of medications and opiate pain medications under the law: permitting the proliferation of opiates and limiting access to treatment.
    Ferrara MM
    Seton Hall Law Rev; 2012; 42(2):741-67. PubMed ID: 22708140
    [No Abstract]   [Full Text] [Related]  

  • 26. Substance abuse prevention and treatment within the criminal justice system: an overview of the issues.
    Campbell-Heider N; Baird C
    J Addict Nurs; 2012 Feb; 23(1):7-13. PubMed ID: 22468655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accessibility versus quality of care plus retention: the formula for service delivery in Australian opioid replacement therapy?
    Harlow W; Roman MW; Happell B; Browne G
    Issues Ment Health Nurs; 2013 Sep; 34(9):706-14. PubMed ID: 24004365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medicaid Coverage for Methadone Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment.
    Saloner B; Stoller KB; Barry CL
    Psychiatr Serv; 2016 Jun; 67(6):676-9. PubMed ID: 26927578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pain, the DEA, and the impact on patients.
    Rowe W
    Pain Med; 2006; 7(1):86. PubMed ID: 16533206
    [No Abstract]   [Full Text] [Related]  

  • 30. Is conventional wisdom wrong? Coverage for substance abuse treatment under Medicaid managed care.
    Maglione M; Ridgely MS
    J Subst Abuse Treat; 2006 Jun; 30(4):285-90. PubMed ID: 16716842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health Insurance Enrollment and Availability of Medications for Substance Use Disorders.
    Abraham AJ; Rieckmann T; Andrews CM; Jayawardhana J
    Psychiatr Serv; 2017 Jan; 68(1):41-47. PubMed ID: 27524366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Societal costs of prescription opioid abuse, dependence, and misuse in the United States.
    Birnbaum HG; White AG; Schiller M; Waldman T; Cleveland JM; Roland CL
    Pain Med; 2011 Apr; 12(4):657-67. PubMed ID: 21392250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can monitoring consumer requests for opioid-replacement therapy improve access to treatment?
    Harlow W; Happell B; Browne G; Browne M
    Aust Health Rev; 2014 Jun; 38(3):312-7. PubMed ID: 24807739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The unique treatment needs of female substance abusers in correctional institutions: the obligation of the criminal justice system to provide parity of services.
    Yang SS
    Med Law; 1990; 9(4):1018-27. PubMed ID: 2125099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Challenges to Opioid Treatment Programs After Hurricane Sandy: Patient and Provider Perspectives on Preparation, Impact, and Recovery.
    Matusow H; Benoit E; Elliott L; Dunlap E; Rosenblum A
    Subst Use Misuse; 2018 Jan; 53(2):206-219. PubMed ID: 28296524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence-based treatment and supervision practices for co-occurring mental and substance use disorders in the criminal justice system.
    Peters RH; Young MS; Rojas EC; Gorey CM
    Am J Drug Alcohol Abuse; 2017 Jul; 43(4):475-488. PubMed ID: 28375656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Criminal Justice Contact and Treatment Utilization Among People With Mental Illness and Substance Use Disorders.
    Nam E; Matejkowski J; Lee S
    Psychiatr Serv; 2016 Oct; 67(10):1149-1151. PubMed ID: 27301764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costs of criminal justice involvement among persons with serious mental illness in connecticut.
    Swanson JW; Frisman LK; Robertson AG; Lin HJ; Trestman RL; Shelton DA; Parr K; Rodis E; Buchanan A; Swartz MS
    Psychiatr Serv; 2013 Jul; 64(7):630-7. PubMed ID: 23494058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What's in a number? Recommending practicality in the DATA 2000 patient limits.
    Barthwell AG; Young JM; Barnes MC; Kulkarni SR
    J Opioid Manag; 2016; 12(4):243-50. PubMed ID: 27575825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges and Opportunities for the Use of Medications to Treat Opioid Addiction in the United States and Other Nations of the World.
    Parrino MW; Maremmani AG; Samuels PN; Maremmani I
    J Addict Dis; 2015; 34(2-3):255-62. PubMed ID: 26110357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.